Company profile
LIQUIDIA CORP
NASDAQ:LQDABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| YUTREPIA | approved | $170.4MQ2 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07285655 | phase3 | recruiting | 2026-04-23 | 2029-07-01 | Liquidia Technologies, Inc. | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD |
| NCT01224262 | phase1_2 | completed | 2010-09-01 | 2011-12-01 | Liquidia Technologies, Inc. | A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 |
| NCT03992755 | phase3 | active_not_recruiting | 2019-07-18 | 2025-05-31 | Liquidia Technologies, Inc. | Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil |
| NCT03884465 | phase2 | terminated | 2019-11-11 | 2020-12-23 | Liquidia Technologies, Inc. | Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil |
| NCT03399604 | phase3 | completed | 2018-01-02 | 2019-05-06 | Liquidia Technologies, Inc. | Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 213005 | 2025-05-23 | NDA | LIQUIDIA TECHNOLOGIES INC | |||||
Loading… | ||||||||